Cancer Institute And Hospital, Chinese Academy Of Medical Sciences

This study tests whether a special PET scan (68Ga-CTR-FAPI) can help surgeons remove all medullary thyroid cancer in one operation. About 150 newly diagnosed patients will be randomly assigned to have surgery guided by this scan or by standard methods. The goal is to see if the s…

This early-phase study tests an inhaled mRNA vaccine called BMD006 for people with advanced lung cancer or solid tumors that have spread to the lungs. The vaccine is designed to train the immune system to attack tumor-related proteins. About 83 participants who have exhausted sta…

This study tests whether giving a targeted drug (anlotinib) along with radiation therapy before surgery can safely reduce major wound complications in adults with soft tissue sarcoma of the arms, legs, or trunk. About 30 participants will receive the combination treatment, and re…

This early-phase trial tests a new treatment called Meta10-TIL for people with advanced solid tumors that have not responded to standard therapies. The treatment uses a patient's own immune cells, which are modified in the lab to better attack cancer. The main goal is to check sa…

This study tests whether combining a targeted chemo procedure (TACE) with two immunotherapy drugs (atezolizumab and bevacizumab) can eliminate or shrink liver cancer before surgery. It involves 30 adults with resectable liver cancer at high risk of coming back. The main goal is t…

This study looks at whether giving the drug tislelizumab before surgery can help people with a specific genetic type of colorectal cancer (dMMR/MSI-H). About 30 adults with stage II or III cancer will receive three doses of tislelizumab, then have surgery to remove the tumor. Res…

This study is testing a new type of radiation therapy that adapts to changes in the body during treatment. It aims to see if this approach can reduce side effects while still controlling the cancer. The trial is for people with prostate cancer that has returned after surgery, or …

This study tests a drug called romiplostim N01 in children and young adults (ages 6-24) whose platelet counts drop dangerously low after chemotherapy. The goal is to see if weekly injections can safely bring platelet levels back up within three weeks. About 50 participants will r…

This study tests whether a low-dose combination of two drugs (cytarabine and thalidomide) can control Langerhans cell histiocytosis (LCH) in adults who have not received prior treatment. LCH is a rare disease where immune cells build up and damage tissues. The trial will enroll 5…

This study tests whether adding the immunotherapy drug tislelizumab after surgery can help prevent early-stage lung cancer from returning in people with high-risk features. About 108 adults with stage I non-small cell lung cancer (tumors 2–4 cm) and at least one high-risk factor …

This study tests whether combining radiation therapy with an immunotherapy drug (sintilimab) is better than a standard liver-directed treatment (TACE) at preventing liver cancer from returning after surgery. It includes 286 adults whose tumors were removed but had narrow margins …

This early-stage study tests a new drug called CREPT-618 in 13 adults with advanced liver cancer that has not responded to standard treatments. The main goal is to check the drug's safety and find the best dose. Researchers will also look at how the drug moves through the body an…

This study aims to find the best treatment before surgery for people with esophageal or stomach cancer. It compares chemotherapy, chemoradiation, targeted therapy, and immunotherapy. The goal is to improve survival and reduce side effects. About 2000 adults with stage I to IVa ca…

This study tests whether customizing radiation, surgery, and additional drug therapy based on how well the tumor responds to initial treatment can improve outcomes for women with advanced breast cancer that has spread to nearby lymph nodes. About 157 participants will receive a p…

This study is for people with biliary tract cancer who have had surgery to remove their tumor. Researchers want to see if using a special test (MiniPDX) to pick the best chemotherapy drugs can help keep the cancer from coming back. About 204 adults will take part, and the study w…

This study tests whether adding the drug sintilimab to standard chemotherapy after surgery can help prevent stage III stomach or GEJ cancer from returning. About 70 adults who have had their tumor removed will receive the combination for up to 16 cycles. The main goal is to see h…

This early-phase study tests an experimental therapy called V001 Injection, which creates cancer-fighting cells directly inside the body. It is for people with advanced blood cancers or solid tumors that have not responded to standard treatments. The main goals are to check safet…

This study compares a new drug, Trastuzumab rezetecan, to standard chemotherapy in 184 adults with advanced HER2-Low breast cancer that has spread and is causing severe organ problems (visceral crisis). Participants receive the drug every three weeks. The main goal is to see if i…

This early-phase trial tests a new cell therapy called Anti-PSMA CAR NK cells in 10 people with metastatic castration-resistant prostate cancer (mCRPC). The goal is to see if the treatment is safe and can slow the cancer. Participants must have a specific marker (PSMA) on their c…

This study tests whether a combination of lenalidomide and dexamethasone can control Rosai-Dorfman disease, a rare condition where immune cells build up and cause swelling. About 40 adults who are newly diagnosed or whose disease has returned will receive the treatment. The goal …

This study tests whether adding golidocitinib to standard PD-1 inhibitor maintenance therapy can help keep extensive-stage small cell lung cancer from progressing. About 20 adults with untreated advanced disease will receive the combination after initial chemo. The goal is to see…

This study tests whether a single injection of Telpegfilgrastim works better than multiple daily injections of Filgrastim to prevent fever and dangerously low white blood cell counts caused by chemotherapy in children and teens (ages 6-24) with solid tumors. About 132 participant…

This study tests two oral drugs, fuzuloparib and apatinib, given before surgery for people with advanced ovarian cancer that has a specific genetic marker (HRD-positive). The goal is to shrink tumors enough for complete removal and avoid chemotherapy. About 48 participants will r…

This study tests a precise type of radiation therapy guided by MRI (MR-linac) for men with prostate cancer that hasn't spread widely. The goal is to see if this approach is well-tolerated, reduces side effects, and improves quality of life. About 50 participants will receive targ…

This study tests whether adding the targeted drug anlotinib to whole-brain radiation helps control brain tumors better than radiation alone in people with small cell lung cancer. About 134 participants will receive either the combination or radiation only. The goal is to see if t…

This study tests a new treatment for men with advanced prostate cancer that has stopped responding to standard hormone therapy. The treatment uses specially designed immune cells (called CAR-NK cells) that are trained to find and attack prostate cancer cells. The main goals are t…

This early study tests a new treatment called GC511B for adults with small cell lung cancer that has come back or not responded to standard therapy. The treatment uses specially engineered immune cells (CAR T cells) to target a protein called DLL3 on cancer cells. The main goals …

This study tests a combination of drugs (liposomal mitoxantrone, capecitabine, and anlotinib) in children, adolescents, and young adults whose solid tumors have returned or not responded to treatment. The goal is to see if this combo can shrink tumors and control the disease. Par…

This study tests whether adding immune checkpoint inhibitors to standard chemotherapy before surgery can improve outcomes for people with locally advanced colorectal cancer. About 170 adults with stage II/III colorectal cancer will be randomly assigned to receive either the combi…

This study aims to find the best treatment plan for people with esophageal or esophagogastric junction cancer that cannot be removed by surgery. It will test adding immunotherapy (PD-1/PD-L1 antibodies) or targeted drugs to the standard chemoradiotherapy. About 2000 adults with s…

This study tests a combination of an immunotherapy drug (adebrelimab) with three chemotherapy drugs given before and after surgery for people with locally advanced stomach or gastroesophageal junction cancer. The goal is to see if this approach can completely eliminate the tumor …

This study tests a combination of three drugs (nimotuzumab, toripalimab, and chemotherapy) as a first treatment for people whose nasopharyngeal cancer has come back or spread. The goal is to see if this mix can shrink tumors and improve survival. About 30 adults with a specific t…

This study is testing a new way of giving radiation before surgery for a rare type of cancer called retroperitoneal sarcoma. The goal is to see if this approach is safe and reduces complications during and after surgery. About 50 adults with this cancer will receive focused radia…

This study tests a new drug combination for people with advanced stomach or gastroesophageal junction cancer that has not responded to initial treatment. About 60 participants will receive either a two-drug or three-drug combination to see if adding a third drug improves outcomes…

This study tests whether adding the drug ivonescimab to standard chemotherapy can shrink liver tumors from colorectal cancer that cannot be removed with surgery. About 40 adults will receive the combination every 3 weeks for up to 8 cycles. The goal is to see if the tumors become…

This study tests whether adding an experimental immunotherapy (QL1706) to standard chemoradiation can help control locally advanced cervical cancer. About 30 women with stage III or IVA cervical cancer will receive the combination treatment. The goal is to see if it improves how …

This study tests a new treatment called LK101, given together with standard immunotherapy drugs, for people with advanced lung cancer that has not responded to previous treatments. The goal is to see if the combination is safe and can shrink tumors. About 60 adults with non-small…

This early-stage study tests a single injection of umbilical cord blood cells (XJ-MK-002) in 16 adults aged 18-75 who have low platelets from cancer therapy. The main goal is to check safety and find the best dose. Researchers will monitor side effects and platelet counts for 28 …

This study tests a new treatment for advanced ovarian cancer patients who have a large amount of fluid in their belly (ascites) and have not responded to standard therapies. The treatment involves injecting specially activated immune cells (SK-NK cells) directly into the abdomen …

This study is testing a new type of PET/CT scan that uses a radioactive tracer called Al18F-octreotide to find tumors that have SSTR proteins on their surface. The goal is to see how accurate this scan is at detecting these tumors. About 400 people with suspected or confirmed SST…

This study is testing a new, non-invasive urine test that looks for a marker called CREPT in cells shed from the bladder. The goal is to see if this test can accurately detect bladder cancer early and monitor for recurrence, potentially replacing more invasive procedures. The stu…

This study looks at whether proteins in urine can help doctors predict how patients with advanced colorectal cancer will respond to treatment before surgery. Researchers will collect urine samples from 400 participants and use advanced technology to find protein patterns linked t…

This study collects long-term survival data from 109 patients with advanced squamous non-small cell lung cancer who previously received tislelizumab combined with chemotherapy in the RATIONALE-307 trial. The goal is to better understand long-term benefits and identify which patie…

This study watches 500 lung cancer patients who received immunotherapy before any other treatment. Researchers want to see if removing the whole lung or just part of it leads to better outcomes, and whether surgery is better than other treatments like radiation. The goal is to le…